Skip to main content

This website is intended exclusively for healthcare professionals residing and/or working in Kuwait.

Home | go to homepage
SCIENCE
  • SCIENCE
  • Cardiovascular
    • Cardiovascular
    • Thrombosis
    • Dyslipidemia
    • Atherothrombosis
  • Atopic Dermatitis
  • Diabetes
  • Asthma
  • Nasal Polyps
  • Rare Diseases
  • Vaccines
    • Vaccines
    • Influenza
    • Pertussis & Polio
    • Meningitis
  • Multiple Sclerosis
PATIENT SUPPORT
  • PATIENT SUPPORT
  • Atopic Dermatitis
  • Rare Diseases
  • Nasal Polyps
  • Diabetes
    • Diabetes
    • Tools And Resources
      • Tools And Resources
      • Digital Patient Support Program
      • My Dose Coach
      • Toujeo Welcome Pack
      • Soliqua Welcome Pack
      • Pre-Ramadan assessment and Risk calculation for diabetic patients during Ramadan
PRODUCTS
  • PRODUCTS
  • Dupixent®
    • Dupixent®
    • Atopic Dermatitis
    • Asthma
    • Nasal Polyps
  • Clexane®
  • Plavix®
  • Apidra®
  • Soliqua®
    • Soliqua®
    • Soliqua®
    • SoliMix Study
    • For a Peaceful Ramadan
  • Praluent®
  • Toujeo®
    • Toujeo®
    • Toujeo®
    • For a Peaceful Ramadan
    • Time-in-Range
  • Lantus®
  • Aubagio®
  • Lemtrada®
  • Amaryl®
  • Depakine®
Home | go to homepage
Home | go to homepage
SCIENCE
  • SCIENCE
  • Cardiovascular
    • Cardiovascular
    • Thrombosis
    • Dyslipidemia
    • Atherothrombosis
  • Atopic Dermatitis
  • Diabetes
  • Asthma
  • Nasal Polyps
  • Rare Diseases
  • Vaccines
    • Vaccines
    • Influenza
    • Pertussis & Polio
    • Meningitis
  • Multiple Sclerosis
PATIENT SUPPORT
  • PATIENT SUPPORT
  • Atopic Dermatitis
  • Rare Diseases
  • Nasal Polyps
  • Diabetes
    • Diabetes
    • Tools And Resources
      • Tools And Resources
      • Digital Patient Support Program
      • My Dose Coach
      • Toujeo Welcome Pack
      • Soliqua Welcome Pack
      • Pre-Ramadan assessment and Risk calculation for diabetic patients during Ramadan
PRODUCTS
  • PRODUCTS
  • Dupixent®
    • Dupixent®
    • Atopic Dermatitis
    • Asthma
    • Nasal Polyps
  • Clexane®
  • Plavix®
  • Apidra®
  • Soliqua®
    • Soliqua®
    • Soliqua®
    • SoliMix Study
    • For a Peaceful Ramadan
  • Praluent®
  • Toujeo®
    • Toujeo®
    • Toujeo®
    • For a Peaceful Ramadan
    • Time-in-Range
  • Lantus®
  • Aubagio®
  • Lemtrada®
  • Amaryl®
  • Depakine®
  • LOGIN
  • REGISTER
  • SEARCH
    • Home
    • Science
    • Cardiovascular

    Cardiovascular Diseases

    Learn about the latest trends, discover events and innovations in the changing world of cardiovascular disease.

    Science in Cardiovascular Diseases

    Get a 360º view and stay up-to-date on cardiovascular disease with content selected for you

    ODYSSEY Outcomes

    NEJM Odyssey Outcomes

    Odyssey Outcomes - Mortality

    VTE Comparison of Pregnancy-Specific Risk Scoring Systems in Hospitalized Maternity Patients

    Utility of Pregnancy-Adapted YEARS Algorithm in Diagnosis of Pulmonary Embolism

    Changing trends in VTE: Pulmonary Embolism Cases on Rise within the Last Decade

    Odyssey Outcomes - CABG Results

    Odyssey Outcomes - PVD Results

    PCSK9 inhibitors and ACS

    Acute Medical Illness: Advanced Age Alone Predicts Venous Thromboembolism Similar to Existing Risk Assessment Models

    VTE prophylaxis in surgical patients

    VTE incidence after cesarean delivery

    SEE EVERYTHING

    Inspiration and innovation

    Get inspired and stay at the forefront of innovation with the following resources

    VTE Comparison of Pregnancy-Specific Risk Scoring Systems in Hospitalized Maternity Patients

    Utility of Pregnancy-Adapted YEARS Algorithm in Diagnosis of Pulmonary Embolism

    PCSK9 inhibitors and ACS

    Key Learnings in Dyslipidemia by Prof. Kausik Ray - 2021 EAS Congress

    Clinical practice experience in patients with familial hypercholesterolemia (FH) from the SAFEHEART registry

    Evaluation of comparative efficacy and safety of thromboprophylaxis agents among critically ill patients

    VTE prophylaxis in medically ill patients

    Evaluation of lipid management following ACS

    Prognostic impact of achieving LDL cholesterol guidelines

    The European experience: SWEDEHEART and AIFA registries

    Understanding de-escalation in antiplatelet therapy

    Clexane Story: 30 Years Of Flowing Life

    SEE EVERYTHING

    Events

    Stay up to date and register for the latest events and view webinar recordings.

    24:30

    Dyslipidemia Webinars: Optimizing Dyslipidemia management​

    VTE prevention for acutely ill patients

    Dyslipidemia Webisodes: Mortality data with Prof. Tunon

    Dyslipidemia Expert Exchange: Best practice approaches in dyslipidemia management

    19:24

    VTE Safety Zone: Assessing the VTE Risk in Hospital and Beyond

    06:13

    VTE Safety Zone: The Role of Thromboprophylaxis for the Prevention of VTE

    VTE Safety Zone: VTE in general surgery from risk assessment to appropriate thromboprophylaxis

    VTE Safety Zone: Prevention of VTE in Medically ill Patients COVID-19 and BEYOND

    06:58

    VTE Safety Zone: Primary VTE Prophylaxis in Patients with Cancer Undergoing Major Abdominal/Pelvic Surgery

    SEE EVERYTHING
    Home | go to homepage

    SANOFI, Level 3, One JLT, Jumeirah Lake Towers (JLT), DMCC, PO Box 53899, Dubai, UAE |

    Tel.: +971 4 550 3600 | Fax: +971 4 5521050

    For further Medical Information:

    please contact: +971 565776791 or Email: medical-information.gulf@sanofi.com

    To report an adverse event:

    please call: +971 561747001 or Email: Gulf.pharmacovigilance@sanofi.com

    To report any product technical complaints, kindly contact: Email: quality.greatergulf@sanofi.com

     

    MAT-KW-2100295/V2/Nov 2021

    • Legal notice
    • Cookie policy
    • Privacy policy
    • Sitemap
    • Change country

    YOU WILL NOW BE LEAVING THE SITE

    By clicking on this link, you will be leaving Campus Sanofi website and going to another, entirely independent website.
    Please note: Sanofi provides these links as a service to its website visitors and users; however, Sanofi takes no responsibility for the information on any website but their own.

    Continue
    This website is intended exclusively for healthcare professionals residing and/or working in Kuwait.
     
    Please choose if you are a healthcare professional and wish to continue on this site or if you are a member of the public to be redirected to the Sanofi website.